<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528801</url>
  </required_header>
  <id_info>
    <org_study_id>480</org_study_id>
    <secondary_id>U54HL070587</secondary_id>
    <secondary_id>U54HL070587-04</secondary_id>
    <nct_id>NCT00528801</nct_id>
  </id_info>
  <brief_title>Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease</brief_title>
  <official_title>Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease
      that can cause intense pain episodes and may lead to organ failure. Preliminary studies have
      shown that adults with SCD may have brain abnormalities that contribute to problems with
      cognitive functioning, including attention and memory difficulties. This study will use brain
      magnetic resonance imaging (MRI) and neuropsychological testing to examine the differences in
      cognitive functioning in adults with SCD and adults without SCD.

      212 subjects participated in this cross-sectional study consisting of screening
      questionnaires, a neuropsychological testing battery, and MRI testing. Enrollment into this
      study ended in May 2008.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and
      intense episodes of pain, which are called &quot;sickle cell crises.&quot; In the past, SCD was
      considered a fatal disease, and many people with SCD died at a young age. Due to advances in
      medical care, people with SCD are now living longer lives; however, they often experience a
      deterioration in quality of life due to progressive organ failure. Past research has
      suggested that children with SCD commonly have frontal lobe dysfunction syndrome, which is a
      brain disorder that can affect cognitive functioning in areas such as attention,
      concentration, information processing, and decision making. Often times, however,
      neurocognitive and brain disorders are not diagnosed or treated in people with SCD. In
      preliminary brain imaging studies, at least half of adult participants with SCD had cognitive
      dysfunction that could be seen in images of the brain, while participants without SCD rarely
      had visible changes in the brain. Brain dysfunction may be one of the most important and
      least-studied problems affecting adults with SCD. The purpose of this study is to evaluate
      the extent of cognitive functioning problems in adults with SCD. The study will also
      determine if there is a connection between cognitive functioning problems and abnormalities
      seen on MRI brain images of adults with SCD.

      This study is an observational case/control study that will enroll adults with SCD and a
      control group of healthy adults who do not have SCD. At a study visit on Day 1, participants
      will undergo blood collection and will complete psychosocial questionnaires. Female
      participants will provide a urine sample for pregnancy testing. Study researchers will
      conduct a medical record review, a physical exam, and a neurological exam. They will also
      interview participants to collect medical history information. On Day 2, participants will
      undergo either a brain MRI or neuropsychological testing; on Day 3, the other procedure will
      be completed. On Day 4, study researchers will explain the study procedure results to
      participants. Participants will be asked if they are willing to take part in a second phase
      of the study in the future. Enrollment into this study ended in May 2008.

      A pilot interventional study follows this study, and is reported separately in
      ClinicalTrials.gov under NCT 00850018.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ</measure>
    <time_frame>Within 2 months of signing informed consent.</time_frame>
    <description>Extent of neurocognitive dysfunction in neurologically asymptomatic adult patients with sickle cell disease as measured by WAIS-III performance IQ. This quotient is based on an average of 100, with a standard deviation of 15. The Wechsler intelligence scales are not considered adequate measures of extremely high and low intelligence (IQ scores above 160 and below 40, respectively). The performance IQ is derived from scores on seven subtests: picture completion, picture arrangement, block design, object assembly, digit symbol, matrix reasoning, and symbol search.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Brain Lacunae as Measured by Clinical MRI</measure>
    <time_frame>Within 2 months of informed consent</time_frame>
    <description>Particpants with imaging abnormalities as measured by MRI (Magnetic Resonance Imaging) specifically brain lacunae. Lacunar infarcts are 3-15 mm in diameter located at the basal ganglia, capsular and thalamic regions. Lesions located at the level of the anterior commisure are considered perivascular spaces unless &gt;5 mm in diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Total Cortical Gray Matter as Measured by Volumetric MRI.</measure>
    <time_frame>Within 2 months of informed consent</time_frame>
    <description>The cortical gray matter is the gray matter of the cerebral cortex only and does not include subcortical gray matter such as hippocampus or basal ganglia.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">212</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>Cases (CLOSED)</arm_group_label>
    <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls (CLOSED)</arm_group_label>
    <description>These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>NP Battery</intervention_name>
    <description>Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.</description>
    <arm_group_label>Cases (CLOSED)</arm_group_label>
    <arm_group_label>Controls (CLOSED)</arm_group_label>
    <other_name>The Weschler Adult Intelligence Scale - Third Edition</other_name>
    <other_name>The Woodcock Johnson Revised - Test of Achievement</other_name>
    <other_name>The Delis-Kaplan Function System</other_name>
    <other_name>The Wisconsin Card Sorting test</other_name>
    <other_name>The Test of Everday Attention</other_name>
    <other_name>The California Verbal Learning Test</other_name>
    <other_name>The Weschler Memory Scales - Third Edition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.</description>
    <arm_group_label>Cases (CLOSED)</arm_group_label>
    <arm_group_label>Controls (CLOSED)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        212 participants, 160 will have sickle cell anemia, 52 will be matched controls based on
        gender, age, and education level
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals who meet all of the following criteria are eligible for enrollment as cases
        into the study:

          1. Adult between the ages of 21 and 55

          2. African descent

          3. Proficient/fluent in English

          4. Hemoglobin electrophoresis confirming hemoglobin SS or SB0 (%A &lt;= 15)

          5. Hemoglobin &lt;= 10 g/dL

          6. Capable of giving informed consent for the protocol

        Individuals who meet all of the following criteria are eligible for enrollment as community
        controls into the study:

          1. Adult between the ages of 21 and 55

          2. African descent

          3. Proficient/fluent in English

          4. Capable of giving informed consent for the protocol

        Exclusion Criteria:

        Individuals who meet any of the following criteria are disqualified from enrollment in the
        case group of the study:

          1. Overt stroke

          2. Previous evidence of an abnormal MRI or CT other than small peri-ventricular or
             watershed lesions

          3. History of head injury that resulted in neurological symptoms or medical visit

          4. Abnormal neurologic exam with focal findings

          5. Mini-Mental Status Examination (MMSE) score of &lt; 20

          6. Profile of Mood States (POMS) score on the Depression-Dejection Subscale suggestive of
             a clinical depression (score &gt; 40)

          7. Alcohol consumption exceeding 14 drinks/week if female, 21 drinks/week if male

          8. Drug abuse, defined as using non-prescribed medication

          9. History of claustrophobia and/or presence of metallic implants such as pacemakers,
             surgical aneurysm clips, or known metal fragments embedded in the body

         10. Pregnancy

         11. Baseline blood pressure &gt; 140/90 on two repeated measurements. A second measurement is
             needed only if the first is &gt; 140/90

         12. History of uncontrolled hypertension

         13. Any chronic disorder that may result in neurocognitive or brain dysfunction that is
             not secondary to SCD including:

               1. Inflammatory arterial disorders (lupus, polyarteritis)

               2. History of cancer requiring chemotherapy and/or radiation

               3. Untreated hyperlipidemia

               4. Diabetes

               5. Ongoing active infection such as HIV, tuberculosis, sarcoidosis

               6. History of chronic transfusion

               7. Chronic renal failure/Dialysis

               8. Chronic lung disease characterized by need for oxygen

               9. Morbid obesity (weight &gt;115 kg)

              10. Heart disease: history of congestive heart failure, history of severe coronary
                  artery disease characterized by angioplasty or surgery, or history of angina

              11. Active hepatitis or liver failure

              12. Acquired or congenital immune deficiency

              13. History of psychoses (delusions, hallucinations) and/or schizophrenia

              14. Neurodegenerative disorders

              15. Genetic disorder associated with neurocognitive dysfunction such as Down Syndrome

              16. Other chronic illness or disorder other than SCD that will adversely affect the
                  subject's performance in the study

         14. Currently on Procrit or related drug that stimulates red blood cell production

        Individuals who meet any of the following criteria are disqualified from enrollment as
        community controls in to the study:

          1. Hb electrophoresis other than AA

          2. Abnormal Hb (females: &lt; 12 g/dL; males: &lt; 13.5 g/dL)

          3. Overt stroke

          4. Previous abnormal MRI or CT

          5. History of head injury that resulted in neurological symptoms or medical visit

          6. Abnormal neurologic exam with focal findings

          7. Mini-Mental Status Examination (MMSE) score of &lt; 20

          8. Profile of Mood States (POMS) score on the Depression-Dejection Subscale suggestive of
             a clinical depression (score &gt; 40)

          9. Alcohol consumption exceeding 14 drinks/week if female, 21 drinks/week if male

         10. Drug abuse, defined as using non-prescribed medication

         11. History of claustrophobia and/or presence of metallic implants such as pacemakers,
             surgical aneurysm clips, or known metal fragments embedded in the body

         12. Pregnancy

         13. Baseline blood pressure &gt; 140/90 on two repeated measurements. A second measurement is
             needed only if the first is &gt; 140/90

         14. History of uncontrolled hypertension

         15. Any chronic disorder that may result in neurocognitive or brain dysfunction including:

               1. Inflammatory arterial disorders (lupus, polyarteritis)

               2. History of cancer requiring chemotherapy and/or radiation

               3. Untreated hyperlipidemia

               4. Diabetes

               5. Ongoing active infection such as HIV, tuberculosis, sarcoidosis

               6. History of chronic transfusion

               7. Chronic renal failure/Dialysis

               8. Chronic lung disease characterized by need for oxygen

               9. Morbid obesity (weight &gt; 115 kg)

              10. Heart disease: history of congestive heart failure, history of severe coronary
                  artery disease characterized by angioplasty or surgery, or history of angina

              11. Active hepatitis or liver failure

              12. Acquired or congenital immune deficiency

              13. History of psychoses (delusions, hallucinations) and/or schizophrenia

              14. Neurodegenerative disorders

              15. Genetic disorder associated with neurocognitive dysfunction such as Down Syndrome

              16. Other chronic illness or disorder that will adversely affect the subject's
                  performance in the study

         16. Currently on Procrit or related drug that stimulates red blood cell production
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliott Vichinsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California CSCC (Children's Hospital Oakland)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>August 28, 2009</results_first_submitted>
  <results_first_submitted_qc>October 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2009</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Elliott Vichinsky</name_title>
    <organization>Children's Hospital of Oakland and Research Institute</organization>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Sickle Cell Anemia</keyword>
  <keyword>Hemoglobin SS</keyword>
  <keyword>Hemoglobin SB0</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with HB SS/SB0 were recruited from 12 sickle cell centers from Dec 2004 through May 2008. To eliminate selection bias, all eligible patients at these centers were approached. Matched peer controls of African descent were recruited from patientsâ€™ community-based churches or neighborhoods, and matched for gender, age and education.</recruitment_details>
      <pre_assignment_details>The NP Battery and the MRI could be scheduled in either order. A 4 week visit window was set between screening and the first of the two procedures. An additional 4 week window was set between the first procedure and the second.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Cases</title>
          <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
        </group>
        <group group_id="P2">
          <title>Phase I: Controls</title>
          <description>These are patients that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Cases</title>
          <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
        </group>
        <group group_id="B2">
          <title>Phase I: Controls</title>
          <description>These are patients that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.57" spread="8.95"/>
                    <measurement group_id="B2" value="33.10" spread="10.06"/>
                    <measurement group_id="B3" value="31.94" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ</title>
        <description>Extent of neurocognitive dysfunction in neurologically asymptomatic adult patients with sickle cell disease as measured by WAIS-III performance IQ. This quotient is based on an average of 100, with a standard deviation of 15. The Wechsler intelligence scales are not considered adequate measures of extremely high and low intelligence (IQ scores above 160 and below 40, respectively). The performance IQ is derived from scores on seven subtests: picture completion, picture arrangement, block design, object assembly, digit symbol, matrix reasoning, and symbol search.</description>
        <time_frame>Within 2 months of signing informed consent.</time_frame>
        <population>Per protocol, no imputation used.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Cases</title>
            <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Controls</title>
            <description>These are patients that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
          </group>
        </group_list>
        <measure>
          <title>Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ</title>
          <description>Extent of neurocognitive dysfunction in neurologically asymptomatic adult patients with sickle cell disease as measured by WAIS-III performance IQ. This quotient is based on an average of 100, with a standard deviation of 15. The Wechsler intelligence scales are not considered adequate measures of extremely high and low intelligence (IQ scores above 160 and below 40, respectively). The performance IQ is derived from scores on seven subtests: picture completion, picture arrangement, block design, object assembly, digit symbol, matrix reasoning, and symbol search.</description>
          <population>Per protocol, no imputation used.</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" spread="12.70"/>
                    <measurement group_id="O2" value="95.9" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between cases and controls in the WAIS-III Perormance IQ (PIQ) Index. A linear model controlling for gender, age, and education was used to compare controls versus cases using an F statistic. Based on sample-size calculations, 120 patients and 36 controls were needed to have 80% power to detect an 8-point difference on the WAIS-III PIQ Index.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for gender, age, and education.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Cases are lower than controls.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Brain Lacunae as Measured by Clinical MRI</title>
        <description>Particpants with imaging abnormalities as measured by MRI (Magnetic Resonance Imaging) specifically brain lacunae. Lacunar infarcts are 3-15 mm in diameter located at the basal ganglia, capsular and thalamic regions. Lesions located at the level of the anterior commisure are considered perivascular spaces unless &gt;5 mm in diameter.</description>
        <time_frame>Within 2 months of informed consent</time_frame>
        <population>Per protocol, no imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Cases</title>
            <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Controls</title>
            <description>These are patients that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Brain Lacunae as Measured by Clinical MRI</title>
          <description>Particpants with imaging abnormalities as measured by MRI (Magnetic Resonance Imaging) specifically brain lacunae. Lacunar infarcts are 3-15 mm in diameter located at the basal ganglia, capsular and thalamic regions. Lesions located at the level of the anterior commisure are considered perivascular spaces unless &gt;5 mm in diameter.</description>
          <population>Per protocol, no imputation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between cases and controls in the proportion of subjects with lacunae. This was tested using a Fisher's Exact Test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in proportions</param_type>
            <param_value>.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>.026</ci_lower_limit>
            <ci_upper_limit>.199</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Total Cortical Gray Matter as Measured by Volumetric MRI.</title>
        <description>The cortical gray matter is the gray matter of the cerebral cortex only and does not include subcortical gray matter such as hippocampus or basal ganglia.</description>
        <time_frame>Within 2 months of informed consent</time_frame>
        <population>Per protocol, no imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Cases</title>
            <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Controls</title>
            <description>These are patients that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Total Cortical Gray Matter as Measured by Volumetric MRI.</title>
          <description>The cortical gray matter is the gray matter of the cerebral cortex only and does not include subcortical gray matter such as hippocampus or basal ganglia.</description>
          <population>Per protocol, no imputations.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="543.5" spread="52.71"/>
                    <measurement group_id="O2" value="569.7" spread="63.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse events or serious adverse events were reported or collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Cases</title>
          <description>These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).</description>
        </group>
        <group group_id="E2">
          <title>Phase I: Controls</title>
          <description>These are patients that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As a cross-sectional study, follow-up of patients not included. Age range of cases and controls not weighted enough to include elder population. Functional or perfusion brain measures not included. Biologic and genetic risk factors not included.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elliott Vichinsky, MD</name_or_title>
      <organization>Children's Hospital of Oakland and Research Institute</organization>
      <phone>510-428-3651</phone>
      <email>evichinsky@mail.cho.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

